

Johan Svensson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4544121/publications.pdf>

Version: 2024-02-01

128
papers

5,038
citations

87888

38
h-index

102487

66
g-index

132
all docs

132
docs citations

132
times ranked

6253
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Liver-Derived Insulin-Like Growth Factor-I. <i>Endocrine Reviews</i> , 2009, 30, 494-535.	20.1	361
2	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3.	10.8	236
3	Malignant Disease and Cardiovascular Morbidity in Hypopituitary Adults with or without Growth Hormone Replacement Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3306-3312.	3.6	206
4	A Prospective Study of 5 Years of GH Replacement Therapy in GH-Deficient Adults: Sustained Effects on Body Composition, Bone Mass, and Metabolic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4657-4665.	3.6	196
5	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
6	Deaths Among Adult Patients With Hypopituitarism: Hypocortisolism During Acute Stress, and De Novo Malignant Brain Tumors Contribute to an Increased Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1466-1475.	3.6	166
7	Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 362-369.	3.6	148
8	Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2121-2127.	3.6	133
9	Insulin-like growth factor-1 in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. <i>Clinical Endocrinology</i> , 1997, 46, 579-586.	2.4	128
10	A 10-Year, Prospective Study of the Metabolic Effects of Growth Hormone Replacement in Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1442-1445.	3.6	111
11	The Activity of the Hypothalamic-Pituitary-Adrenal Axis and the Sympathetic Nervous System in Relation to Waist/Hip Circumference Ratio in Men. <i>Obesity</i> , 2000, 8, 487-495.	4.0	104
12	Baseline Characteristics and the Effects of Five Years of GH Replacement Therapy in Adults with GH Deficiency of Childhood or Adulthood Onset: A Comparative, Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4693-4699.	3.6	98
13	Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1943-1945.	2.0	98
14	Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1417-1441.	2.6	90
15	Five Years of Growth Hormone Replacement Therapy in Adults: Age- and Gender-Related Changes in Isometric and Isokinetic Muscle Strength. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2061-2069.	3.6	89
16	Fifteen years of GH replacement improves body composition and cardiovascular risk factors. <i>European Journal of Endocrinology</i> , 2013, 168, 745-753.	3.7	89
17	Genomewide meta-analysis identifies loci associated with IGF and IGFBP levels with impact on age-related traits. <i>Aging Cell</i> , 2016, 15, 811-824.	6.7	83
18	Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. <i>European Journal of Endocrinology</i> , 2007, 156, 55-64.	3.7	70

#	ARTICLE	IF	CITATIONS
19	Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 362-369.	3.6	68
20	Ten Years of Growth Hormone (GH) Replacement Normalizes Muscle Strength in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 809-816.	3.6	68
21	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 537-546.	2.6	68
22	The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 114-131.	4.3	67
23	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1729-1737.	2.7	66
24	Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice. <i>Journal of Endocrinology</i> , 2006, 189, 617-627.	2.6	62
25	The amyloid- β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014, 573, 7-12.	2.1	62
26	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 34-39.	3.5	60
27	Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. <i>Growth Hormone and IGF Research</i> , 2004, 14, 207-215.	1.1	56
28	Liver-Derived IGF-I Regulates Mean Life Span in Mice. <i>PLoS ONE</i> , 2011, 6, e22640.	2.5	53
29	Leukocyte telomere length is not associated with mortality in older men. <i>Experimental Gerontology</i> , 2014, 57, 6-12.	2.8	48
30	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. <i>Translational Psychiatry</i> , 2016, 6, e952-e952.	4.8	46
31	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e81989.	2.5	45
32	Nonfatal Stroke, Cardiac Disease, and Diabetes Mellitus in Hypopituitary Patients on Hormone Replacement Including Growth Hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3560-3567.	3.6	44
33	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. <i>Experimental Gerontology</i> , 2012, 47, 179-182.	2.8	44
34	The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. <i>Clinical Endocrinology</i> , 2005, 62, 105-113.	2.4	42
35	Alzheimer's disease—subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 95-113.	4.3	42
36	Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2004, 60, 550-559.	2.4	40

#	ARTICLE	IF	CITATIONS
37	Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany. <i>European Journal of Endocrinology</i> , 2006, 154, 843-850.	3.7	40
38	Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 637-646.	2.6	40
39	Both Low and High Serum IGF-1 Levels Associate With Increased Risk of Cardiovascular Events in Elderly Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2308-E2316.	3.6	39
40	Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2121-2127.	3.6	39
41	Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. <i>Bone</i> , 2006, 38, 85-92.	2.9	38
42	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1058-1066.	2.7	38
43	Management of growth hormone deficiency in adults. <i>Growth Hormone and IGF Research</i> , 2007, 17, 441-462.	1.1	36
44	Safety aspects of GH replacement. <i>European Journal of Endocrinology</i> , 2009, 161, S65-S74.	3.7	36
45	Stimulation of both estrogen and androgen receptors maintains skeletal muscle mass in gonadectomized male mice but mainly via different pathways. <i>Journal of Molecular Endocrinology</i> , 2010, 45, 45-57.	2.5	36
46	Baseline Characteristics and the Effects of Five Years of GH Replacement Therapy in Adults with GH Deficiency of Childhood or Adulthood Onset: A Comparative, Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4693-4699.	3.6	36
47	Both Low and High Serum IGF-I Levels Associate with Cancer Mortality in Older Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4623-4630.	3.6	35
48	Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4408-4414.	3.6	33
49	Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2531-2538.	3.6	33
50	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 283-294.	1.3	33
51	Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2019, 99, 112-119.	2.7	33
52	Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 1158-1166.	2.8	32
53	Sleep apnoea and quality of life in growth hormone (GH)-deficient adults before and after 6 months of GH replacement therapy. <i>Clinical Endocrinology</i> , 2006, 65, 98-105.	2.4	31
54	Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. <i>European Journal of Endocrinology</i> , 2017, 176, 99-109.	3.7	31

#	ARTICLE	IF	CITATIONS
55	Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin-like growth factor I axis in growth hormone–deficient children. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 91-98.	4.7	29
56	Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 96-107.	2.4	29
57	The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. <i>Journal of Endocrinology</i> , 2000, 165, 569-577.	2.6	25
58	Growth hormone (GH) replacement therapy in GH deficient adults: Predictors of one-year metabolic and clinical response. <i>Growth Hormone and IGF Research</i> , 2007, 17, 67-76.	1.1	25
59	Serum Insulin-Like Growth Factor-I Concentration Is Associated with Leukocyte Telomere Length in a Population-Based Cohort of Elderly Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 5078-5084.	3.6	25
60	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1017-1026.	2.6	24
61	Altered thyroid hormone profile in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2020, 121, 104844.	2.7	21
62	Effects of Growth Hormone and Its Secretagogues on Bone. <i>Endocrine</i> , 2001, 14, 063-066.	2.2	20
63	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 609, 58-62.	2.1	20
64	Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. <i>Psychoneuroendocrinology</i> , 2017, 86, 169-175.	2.7	20
65	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. <i>Scientific Reports</i> , 2019, 9, 5522.	3.3	20
66	Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2003, 58, 572-580.	2.4	19
67	Increased Neck Soft Tissue Mass and Worsening of Obstructive Sleep Apnea after Growth Hormone Treatment in Men with Abdominal Obesity. <i>Journal of Clinical Sleep Medicine</i> , 2010, 06, 256-263.	2.6	19
68	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1039-1049.	2.6	19
69	Importance of circulating IGF-1 for normal cardiac morphology, function and post infarction remodeling. <i>Growth Hormone and IGF Research</i> , 2012, 22, 206-211.	1.1	19
70	Growth Hormone Replacement Therapy and Insulin Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1453-1454.	3.6	18
71	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017, 19, 154-160.	3.4	18
72	Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. <i>PLoS ONE</i> , 2017, 12, e0176760.	2.5	18

#	ARTICLE	IF	CITATIONS
73	Adiponectin, Leptin, and Erythrocyte Sodium/Lithium Countertransport Activity, But Not Resistin, Are Related to Glucose Metabolism in Growth Hormone-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2290-2296.	3.6	17
74	Liver-derived IGF-I regulates kidney size, sodium reabsorption, and renal IGF-II expression. <i>Journal of Endocrinology</i> , 2007, 193, 359-366.	2.6	17
75	A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. <i>Growth Hormone and IGF Research</i> , 2000, 10, 118-126.	1.1	16
76	Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients - a prospective observational study. <i>BMC Neurology</i> , 2019, 19, 177.	1.8	16
77	Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a)1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2028-2033.	3.6	15
78	Liver-derived IGF1 enhances the androgenic response in prostate. <i>Journal of Endocrinology</i> , 2008, 199, 489-497.	2.6	15
79	Deficiency of liver-derived insulin-like growth factor-I (IGF-I) does not interfere with the skin wound healing rate. <i>PLoS ONE</i> , 2018, 13, e0193084.	2.5	15
80	Growth hormone and the cardiovascular function. <i>Minerva Endocrinologica</i> , 2005, 30, 1-13.	1.8	15
81	Thigh intermuscular fat is inversely associated with spontaneous GH release in post-menopausal women with abdominal obesity. <i>European Journal of Endocrinology</i> , 2006, 155, 261-268.	3.7	14
82	Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy. <i>Psychoneuroendocrinology</i> , 2013, 38, 842-852.	2.7	14
83	Altered levels of circulating insulin-like growth factor I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study. <i>BMC Neurology</i> , 2018, 18, 106.	1.8	14
84	Liver-derived IGF-I regulates exploratory activity in old mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E466-E473.	3.5	13
85	Liver-derived endocrine IGF-I is not critical for activation of skeletal muscle protein synthesis following oral feeding. <i>BMC Physiology</i> , 2013, 13, 7.	3.6	13
86	The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen-deficient women. <i>Growth Hormone and IGF Research</i> , 2009, 19, 112-120.	1.1	12
87	Liver-derived IGF-I regulates cortical bone mass but is dispensable for the osteogenic response to mechanical loading in female mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E138-E144.	3.5	12
88	Increased Orderliness of Growth Hormone (GH) Secretion in GH-Deficient Adults with Low Serum Insulin-Like Growth Factor I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2863-2869.	3.6	11
89	Different modes of GH administration influence gene expression in the male rat brain. <i>Journal of Endocrinology</i> , 2014, 222, 181-190.	2.6	11
90	Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 289-298.	2.6	10

#	ARTICLE	IF	CITATIONS
91	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 729-741.	2.6	10
92	Growth Hormone and Neuronal Hemoglobin in the Brain – Roles in Neuroprotection and Neurodegenerative Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 606089.	3.5	10
93	Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a). <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2028-2033.	3.6	9
94	Effects of GH and insulin-like growth factor-I on body composition. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 823-831.	3.3	9
95	Long-Term Efficacy and Safety of Somatropin for Adult Growth Hormone Deficiency. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2003, 2, 109-120.	1.8	9
96	Serum erythropoietin and outcome after ischaemic stroke: a prospective study. <i>BMJ Open</i> , 2016, 6, e009827.	1.9	9
97	Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12031.	2.4	9
98	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	2.5	9
99	Increased diet-induced fatty streak formation in female mice with deficiency of liver-derived insulin-like growth factor-I. <i>Endocrine</i> , 2016, 52, 550-560.	2.3	8
100	Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 405-414.	2.1	8
101	Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 597-607.	2.6	8
102	Body Composition and Quality of Life as Markers of the Efficacy of Growth Hormone Replacement Therapy in Adults. <i>Hormone Research in Paediatrics</i> , 2001, 55, 55-60.	1.8	7
103	Mode of GH administration and gene expression in the female rat brain. <i>Journal of Endocrinology</i> , 2017, 233, 187-196.	2.6	7
104	Identifying the Value of an eHealth Intervention Aimed at Cognitive Impairments: Observational Study in Different Contexts and Service Models. <i>Journal of Medical Internet Research</i> , 2020, 22, e17720.	4.3	7
105	Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. <i>Clinical Endocrinology</i> , 1999, 50, 451-456.	2.4	6
106	Growth hormone secretagogues. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 1071-1080.	5.0	6
107	Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation. <i>Growth Hormone and IGF Research</i> , 2013, 23, 249-255.	1.1	6
108	Association Between Levels of Serum Insulin-like Growth Factor I and Functional Recovery, Mortality, and Recurrent Stroke at a 7-year Follow-up. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 303-310.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Subclinical hyperthyroidism is associated with increased risk of vertebral fractures in older men. <i>Osteoporosis International</i> , 2021, 32, 2257-2265.	3.1	6
110	The Importance of Growth Hormone (GH) and GH Secretagogues for Bone Mass and Density. <i>Current Pharmaceutical Design</i> , 2002, 8, 2023-2032.	1.9	5
111	Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein ¹² in patients with subcortical small-vessel disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12296.	2.4	5
112	GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. <i>European Journal of Endocrinology</i> , 2006, 155, 91-99.	3.7	4
113	Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism – A pilot study. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 19, 100218.	1.4	4
114	Effects of peripheral administration of GH and IGF-I on gene expression in the hippocampus of hypophysectomised rats. <i>Neuroendocrinology Letters</i> , 2019, 39, 525-531.	0.2	4
115	Higher thyroid function is associated with accelerated hippocampal volume loss in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2022, 139, 105710.	2.7	4
116	The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. <i>Growth Hormone and IGF Research</i> , 2003, 13, 1-7.	1.1	3
117	Liver-derived IGF-I is not required for protection against osteoarthritis in male mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E1150-E1157.	3.5	3
118	Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 781-790.	2.6	3
119	Testosterone associates differently with body mass index and age in serum and cerebrospinal fluid in men. <i>Journal of Internal Medicine</i> , 2022, 292, 684-686.	6.0	3
120	Growth hormone secretagogues as therapeutic agents. <i>Growth Hormone and IGF Research</i> , 1999, 9, 107-109.	1.1	2
121	Relationship between Levels of Pre-Stroke Physical Activity and Post-Stroke Serum Insulin-Like Growth Factor I. <i>Biomedicines</i> , 2020, 8, 52.	3.2	2
122	Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1373-1383.	2.6	2
123	Insulin-like growth factor I and risk of incident cancer in elderly men – results from MrOS (Osteoporotic Fractures in Men) in Sweden. <i>Clinical Endocrinology</i> , 2016, 84, 764-770.	2.4	1
124	Latent Cognitive Profiles Differ Between Incipient Alzheimer's Disease and Dementia with Subcortical Vascular Lesions in a Memory Clinic Population. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 955-966.	2.6	1
125	Insulin-Like Growth Factor-II and Ischemic Stroke – A Prospective Observational Study. <i>Life</i> , 2021, 11, 499.	2.4	1
126	Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1007-1016.	2.6	1

#	ARTICLE	IF	CITATIONS
127	The Anabolic Effects of Growth Hormone (GH) and GH Secretagogues on Bone Mass and Density. Medicinal Chemistry Reviews Online, 2005, 2, 1-9.	0.1	0
128	Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. Neurological Research, 2021, 43, 1013-1022.	1.3	0